ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Care

Kirin beefs up health business to make up for beer slump

Brewer to raise output of ingredient used in drugs to treat brain disease

Kirin subsidiary Kyowa Hakko Bio will will expand a plant in Yamaguchi Prefecture, with the additonal production expected to begin in the summer of 2023. 

TOKYO -- Japanese brewer Kirin Holdings will spend 7.7 billion yen ($73 million) to raise production of an ingredient found in drugs used to treat brain disease and in health supplements, as the company shifts its focus in response to the aging of its home market.

Its Kyowa Hakko Bio subsidiary will expand its factory in Japan's western Yamaguchi Prefecture, with additional production expected to begin in the summer of 2023. The expansion will raise its capacity two and a half times from the current level.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more